- Home
- WEA vs GNLX Comparison
WEA vs GNLX Comparison
Compare WEA & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WEA | GNLX |
|---|---|---|
| Founded | 2002 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.4M | 110.4M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | WEA | GNLX |
|---|---|---|
| Price | $9.66 | $1.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.83 |
| AVG Volume (30 Days) | 65.9K | ★ 429.6K |
| Earning Date | 01-01-0001 | 11-24-2026 |
| Dividend Yield | ★ 7.87% | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.52 | $1.77 |
| 52 Week High | $11.42 | $5.89 |
Technical Indicators
Market Signals| Indicator | WEA | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 38.35 |
| Support Level | $9.55 | $1.82 |
| Resistance Level | $10.46 | $2.69 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 21.05 | 16.00 |
Price Performance
Historical ComparisonAbout WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The fund invests in bonds of companies operating in different sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.